The Q4 result was announced after market hours on Wednesday, 15 May 2013.

Meanwhile, the S&P BSE Sensex was up 71.58 points or 0.35% at 20,284.54.

On BSE, 2.02 lakh shares were traded in the counter as against average daily volume of 4.69 lakh shares in the past one quarter.

The stock hit a high of Rs 63.70 and a low of Rs 60.30 so far during the day. The stock had hit a 52-week low of Rs 53 on 4 March 2013. The stock had hit a 52-week high of Rs 135.10 on 15 May 2012.

The stock had underperformed the market over the past one month till 15 May 2013, surging 4.86% compared with the Sensex's 10.11% rally. The scrip had also underperformed the market in past one quarter, declining 8.17% as against Sensex's 3.83% rise.

The small-cap pharmaceutical company has equity capital of Rs 70.45 crore. Face value per share is Rs 10.

Orchid Chemicals & Pharmaceuticals' revenue declined 45.36% to Rs 268.16 crore in quarter ended 31 March 2013 over the quarter ended 31 March 2012.

Earnings before interest, taxation, depreciation and amortization (EBITDA) crashed 84.37% to Rs 13.98 crore in the quarter ended 31 March 2013 over the quarter ended 31 March 2012.

Orchid Chemicals & Pharmaceuticals reported net loss of Rs 275.37 crore for the twelve months ended 31 March 2013, as against net profit of Rs 103.11 crore for the twelve months ended 31 March 2012. EBITDA slumped 67.79% to Rs 132.58 crore in the twelve months ended 31 March 2013 over the twelve months ended 31 March 2012.

Orchid Chemicals & Pharmaceuticals has extended its financial year FY 2013 by 3 months to 30 June 2013 from 31 March 2013.

Orchid Chemicals & Pharmaceuticals is involved in the development, manufacture and marketing of diverse bulk activities, formulations and nutraceuticals.